

GILEAD SCIENCES INC  
Form 8-K  
July 31, 2007

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

July 30, 2007

Gilead Sciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware

0-19731

94-3047598

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(I.R.S. Employer  
Identification No.)

333 Lakeside Drive, Foster City, California

94404

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

650-574-3000

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Top of the Form**

**Item 8.01 Other Events.**

On July 30, 2007, James M. Denny, Chairman of the Board of Directors of Gilead Sciences, Inc., a Delaware corporation (the Company), entered into a new stock trading plan under Rule 10b5-1 of the Securities Exchange Act of 1934 (Rule 10b5-1). Paul Berg, Ph.D., a member of the Company's Board of Directors, John C. Martin, Ph.D., President and Chief Executive Officer and a member of the Company's Board of Directors, John F. Milligan, Ph.D., Chief Operating Officer and Chief Financial Officer, Kevin Young, Executive Vice President, Commercial Operations and Gregg H. Alton, Senior Vice President and General Counsel of the Company, previously established stock trading plans under Rule 10b5-1, and certain other officers and directors of the Company may do so in the future. A copy of the press release is filed as Exhibit 99.1 to this report.

The information in this Form 8-K and the exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

Exhibit Number Description

99.1 Press Release, issued by Gilead Sciences, Inc. on July 31, 2007.

**Top of the Form**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Gilead Sciences, Inc.

*July 31, 2007*

By: */s/ John F. Milligan, Ph.D.*

---

*Name: John F. Milligan, Ph.D.*

*Title: Chief Operating Officer and Chief Financial Officer*

---

Edgar Filing: GILEAD SCIENCES INC - Form 8-K

**Top of the Form**

Exhibit Index

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release, issued by Gilead Sciences, Inc. on July 31, 2007.